Cover Image
市場調查報告書

疤痕增長症 : 開發平台分析

Keloids - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 257827
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
疤痕增長症 : 開發平台分析 Keloids - Pipeline Review, H2 2015
出版日期: 2015年09月09日 內容資訊: 英文 49 Pages
簡介

所謂疤痕增長症是指皮膚受傷回復後疤痕組織過度增殖這樣的疾病。主要症狀有皮膚變為肉色(紅·粉紅等),大量產生疙瘩,皮膚僵硬化,摩擦服裝類等時候會感到發癢,容易受傷等。主要的風險要素有年齡和家族病史等。主要的治療方法有皮質類固醇和放射治療,外科摘除手術,矽凝膠,膏藥等。

本報告提供全球各國治療疤痕增長症用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

疤痕增長症概要

治療藥的開發

  • 疤痕增長症開發中產品:概要
  • 疤痕增長症開發中產品:比較分析

各企業開發中的疤痕增長症治療藥

大學/研究機關研究中的疤痕增長症治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

疤痕增長症治療藥:開發中的產品一覽(各企業)

疤痕增長症治療藥:研究中的產品一覽(大學/研究機關別)

疤痕增長症治療藥的開發企業

  • RXi Pharmaceuticals Corporation
  • Vida Therapeutics Inc.

疤痕增長症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • CIGB-128
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • CM-101
  • koebnerisin
  • psoriasin
  • RXI-109
  • V-2248
  • VTI-3000 Series

疤痕增長症治療藥:開發中產品的最新趨勢

疤痕增長症治療藥:暫停開發的產品

疤痕增長症治療藥:中止開發的產品

疤痕增長症相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7138IDB

Summary

Global Markets Direct's, 'Keloids - Pipeline Review, H2 2015', provides an overview of the Keloids's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Keloids, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keloids and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Keloids
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Keloids and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Keloids products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Keloids pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Keloids
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Keloids pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Keloids Overview
  • Therapeutics Development
    • Pipeline Products for Keloids - Overview
    • Pipeline Products for Keloids - Comparative Analysis
  • Keloids - Therapeutics under Development by Companies
  • Keloids - Therapeutics under Investigation by Universities/Institutes
  • Keloids - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Keloids - Products under Development by Companies
  • Keloids - Products under Investigation by Universities/Institutes
  • Keloids - Companies Involved in Therapeutics Development
    • RXi Pharmaceuticals Corporation
    • Vida Therapeutics Inc.
  • Keloids - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CIGB-128 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CM-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • koebnerisin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • psoriasin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RXI-109 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • V-2248 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VTI-3000 Series - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Keloids - Recent Pipeline Updates
  • Keloids - Dormant Projects
  • Keloids - Discontinued Products
  • Keloids - Product Development Milestones
    • Featured News & Press Releases
      • Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology
      • Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study
      • Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders
      • Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
      • Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision
      • Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109
      • Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Keloids, H2 2015
  • Number of Products under Development for Keloids - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Keloids - Pipeline by RXi Pharmaceuticals Corporation, H2 2015
  • Keloids - Pipeline by Vida Therapeutics Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Keloids Therapeutics - Recent Pipeline Updates, H2 2015
  • Keloids - Dormant Projects, H2 2015
  • Keloids - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Keloids, H2 2015
  • Number of Products under Development for Keloids - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top